受精障礙
受精障礙是指受精過程中出現異常,導致卵母細胞無法正常受精的現象。根據異常情況可分為受精失敗(total fertilization failure, TFF)和異常受精(abnormal fertilization)。受精失敗指卵母細胞未形成原核,而異常受精則指卵母細胞中原核數量異常(不等於2個)[1]。這類障礙可導致不孕不育。體外人工受精(IVF)的受精障礙發生率為5-10%,主要由於精子和卵母細胞識別或融合異常所致[2][3]。
診斷
[編輯]由於受精障礙可能發生在受精過程的不同階段,其臨床表現具有異質性,需通過多種檢測手段進行分型和診斷[1]。
使用計算機輔助精子分析(computer-aided sperm analysis,CASA)可檢測精子運動軌跡和超活化能力,尤其對存在CATSPER基因突變的患者,可提前識別超活化能力異常[4]。採用巴氏染色法可識別圓頭精子症患者,而頂體錨定異常患者需藉助透射電子顯微鏡進一步分析[1]。檢測精子頂體內的酶活性(如精氨酸醯胺酶活性)可識別IVF受精失敗的高風險患者[5]。
採用小鼠卵母細胞激活試驗(mouse oocyte activation test,MOAT)或人卵母細胞激活試驗(human oocyte activation test,HOAT)評估精子激活能力,有助於明確障礙是由精子或卵母細胞引起[6][1]。
通過免疫螢光染色檢測精子中PLCζ陽性率及定位,可為IVF受精率的評估提供參考[7]。利用全外顯子測序(whole exome sequencing,WES)可篩查與受精障礙相關的基因突變[1]。
治療
[編輯]胞漿內精子注射技術(ICSI)通過將單個精子直接注入卵胞質內,可解決大部分因識別或融合異常導致的受精障礙,但ICSI的受精障礙發生率仍在1%-3%[8]。在受精失敗後對未受精卵母細胞實施補救ICSI(Re-ICSI),包括早補救和晚補救ICSI。早補救ICSI在IVF授精後4-6小時進行,可降低周期取消率;晚補救ICSI在16-18小時後進行,儘管成功率較低,但可評估下一周期治療效果。[1]
卵母細胞輔助激活(assisted oocyte activation,AOA)通過機械、電或化學刺激提高卵胞質內鈣離子濃度,改善因卵母細胞激活障礙導致的受精失敗[9][1]。最常用化學刺激法,將注射完精子後的卵母細胞暴露在離子黴素和鈣黴素等化學試劑中來增加卵胞質內鈣離子濃度[1][10]。
對受精障礙患者進行遺傳諮詢有助於評估基因突變對生育的影響和後代的遺傳風險。諮詢一般包括兩次:第一次介紹可能原因並建議基因檢測;第二次解讀檢測結果並提出治療建議。[1]
參考文獻
[編輯]- ^ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 Dai, Jing; Huang, YiLian; Lin, Ge. Genetic mechanisms of infertility due to fertilization deficiency. SCIENTIA SINICA Vitae. 2024-11-01, 54 (11): 2112–2124. doi:10.1360/SSV-2024-0148.
- ^ Georgadaki, Katerina; Khoury, Nikolas; Spandidos, Demetrios A.; Zoumpourlis, Vasilis. The molecular basis of fertilization (Review). International Journal of Molecular Medicine. 2016-10, 38 (4): 979–986. doi:10.3892/ijmm.2016.2723.
- ^ Hirose, Michiko; Honda, Arata; Fulka, Helena; Tamura-Nakano, Miwa; Matoba, Shogo; Tomishima, Toshiko; Mochida, Keiji; Hasegawa, Ayumi; Nagashima, Kiyoshi; Inoue, Kimiko; Ohtsuka, Masato; Baba, Tadashi; Yanagimachi, Ryuzo; Ogura, Atsuo. Acrosin is essential for sperm penetration through the zona pellucida in hamsters. Proceedings of the National Academy of Sciences. 2020-02-04, 117 (5): 2513–2518. doi:10.1073/pnas.1917595117.
- ^ Young, Samuel; Schiffer, Christian; Wagner, Alice; Patz, Jannika; Potapenko, Anton; Herrmann, Leonie; Nordhoff, Verena; Pock, Tim; Krallmann, Claudia; Stallmeyer, Birgit; Röpke, Albrecht; Kierzek, Michelina; Biagioni, Cristina; Wang, Tao; Haalck, Lars; Deuster, Dirk; Hansen, Jan N.; Wachten, Dagmar; Risse, Benjamin; Behre, Hermann M.; Schlatt, Stefan; Kliesch, Sabine; Tüttelmann, Frank; Brenker, Christoph; Strünker, Timo. Human fertilization in vivo and in vitro requires the CatSper channel to initiate sperm hyperactivation. Journal of Clinical Investigation. 2024-01-02, 134 (1). doi:10.1172/JCI173564.
- ^ Hu, Ye-Na; Hu, Liang; Yin, Xin-Yu; Zhang, Huan; Peng, Yang-Qin; Liu, Gang; Lin, Ge; Li, Wei-Na. Sperm acrosin activity may be a useful factor in choosing between ICSI and IVF for infertile male patients. Asian Journal of Andrology. 2024-01, 26 (1): 85–90. doi:10.4103/aja202337.
- ^ Heindryckx, B.; Van der Elst, J.; De Sutter, P.; Dhont, M. Treatment option for sperm- or oocyte-related fertilization failure: assisted oocyte activation following diagnostic heterologous ICSI. Human Reproduction. 2005-08-01, 20 (8): 2237–2241. doi:10.1093/humrep/dei029.
- ^ Che, Jian-Fang; Wu, Hui-Xia; Zeng, Si-Cong; Wu, Yue-Ren; Dai, Jing; Cheng, De-Hua; Gong, Fei; Lu, Guang-Xiu; Lin, Ge; Dai, Can. Defects in phospholipase C zeta cause polyspermy and low fertilization after conventional IVF: not just ICSI failure. Asian Journal of Andrology. 2024-03, 26 (2): 175–182. doi:10.4103/aja202355.
- ^ Torra-Massana, Marc; Rodríguez, Amelia; Vassena, Rita. Exonic genetic variants associated with unexpected fertilization failure and zygotic arrest after ICSI: a systematic review. Zygote. 2023-08, 31 (4): 316–341. doi:10.1017/S096719942300014X.
- ^ Vanden Meerschaut, Frauke; Nikiforaki, Dimitra; Heindryckx, Björn; De Sutter, Petra. Assisted oocyte activation following ICSI fertilization failure. Reproductive BioMedicine Online. 2014-05, 28 (5): 560–571. doi:10.1016/j.rbmo.2014.01.008.
- ^ Kashir, Junaid; Ganesh, Durga; Jones, Celine; Coward, Kevin. Oocyte activation deficiency and assisted oocyte activation: mechanisms, obstacles and prospects for clinical application. Human Reproduction Open. 2022-03-04, 2022 (2). doi:10.1093/hropen/hoac003.